Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Interleukin-29 suppresses hepatitis A and C viral internal ribosomal entry site-mediated translation.

Literature DB >> 23035851

Interleukin-29 suppresses hepatitis A and C viral internal ribosomal entry site-mediated translation.

Tatsuo Kanda¹, Shuang Wu, Tomoko Kiyohara, Shingo Nakamoto, Xia Jiang, Tatsuo Miyamura, Fumio Imazeki, Koji Ishii, Takaji Wakita, Osamu Yokosuka.

Abstract

Our aim was to investigate the effects of interferons (IFNs)-λ (interleukin-29 [IL-29], IL-28A, and IL-28B) on hepatitis C virus (HCV) and hepatitis A virus (HAV) internal ribosomal entry site (IRES)-mediated translation. The effects of these IFNs on HCV/HAV translation from HAV/HCV IRES were investigated using bicistronic reporter constructs. We transfected HCV/HAV IRES constructs into these IFN-expressing cell lines. IL-29 showed stronger inhibition of their IRES-mediated translation. Combining IL-29 with IFN-α or amantadine resulted in stronger inhibition of HAV IRES activity. Our findings demonstrated a novel antiviral effect of IFNs-λ against HAV and HCV through the suppression of IRES-mediated translation.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2012 PMID： 23035851 DOI： 10.1089/vim.2012.0021

Source DB: PubMed Journal: Viral Immunol ISSN： 0882-8245 Impact factor: 2.257

Keyword Cloud
Cited

10 in total

1. Interferon and ribavirin combination treatment synergistically inhibit HCV internal ribosome entry site mediated translation at the level of polyribosome formation.

Authors: Rajesh Panigrahi; Sidhartha Hazari; Sruti Chandra; Partha K Chandra; Sibnarayan Datta; Ramazan Kurt; Craig E Cameron; Zhuhui Huang; Haitao Zhang; Robert F Garry; Luis A Balart; Srikanta Dash
Journal: PLoS One Date: 2013-08-23 Impact factor: 3.240

Review 2. Direct-acting Antivirals and Host-targeting Agents against the Hepatitis A Virus.

Authors: Tatsuo Kanda; Shingo Nakamoto; Shuang Wu; Masato Nakamura; Xia Jiang; Yuki Haga; Reina Sasaki; Osamu Yokosuka
Journal: J Clin Transl Hepatol Date: 2015-09-15

Review 3. Cell Culture Systems and Drug Targets for Hepatitis A Virus Infection.

Authors: Tatsuo Kanda; Reina Sasaki; Ryota Masuzaki; Naoki Matsumoto; Masahiro Ogawa; Mitsuhiko Moriyama
Journal: Viruses Date: 2020-05-12 Impact factor: 5.048

Review 4. The role of IL-29 in immunity and cancer.

Authors: Noah E Kelm; Ziwen Zhu; Vivi A Ding; Huaping Xiao; Mark R Wakefield; Qian Bai; Yujiang Fang
Journal: Crit Rev Oncol Hematol Date: 2016-08-10 Impact factor: 6.312

Review 5. Co-Occurrence of Hepatitis A Infection and Chronic Liver Disease.

Authors: Tatsuo Kanda; Reina Sasaki; Ryota Masuzaki; Hiroshi Takahashi; Taku Mizutani; Naoki Matsumoto; Kazushige Nirei; Mitsuhiko Moriyama
Journal: Int J Mol Sci Date: 2020-09-02 Impact factor: 5.923

6. Favipiravir Inhibits Hepatitis A Virus Infection in Human Hepatocytes.

Authors: Reina Sasaki-Tanaka; Toshikatsu Shibata; Hiroaki Okamoto; Mitsuhiko Moriyama; Tatsuo Kanda
Journal: Int J Mol Sci Date: 2022-02-27 Impact factor: 5.923

Review 7. Current Practice in Bicistronic IRES Reporter Use: A Systematic Review.

Authors: Guus Gijsbertus Hubert van den Akker; Federico Zacchini; Bas Adrianus Catharina Housmans; Laura van der Vloet; Marjolein Maria Johanna Caron; Lorenzo Montanaro; Tim Johannes Maria Welting
Journal: Int J Mol Sci Date: 2021-05-14 Impact factor: 5.923